Sironax is a Beijing-based clinical-stage biotechnology company dedicated to discovering and developing novel treatments for patients with age-related degenerative diseases. Its pipeline comprises multiple programs focused on key mechanisms including regulated cell death, neuroprotective pathways and neuroinflammation, with lead efforts around RIPK1 inhibitors. The company is conducting early clinical studies with SIR0365 and SIR2446 while advancing additional preclinical research. Sironax plans to use recent financing to support ongoing clinical development of its RIPK1 portfolio and to expand its R&D footprint and pipeline of potential best- and first-in-class candidates. The company closed a $200M Series B led by Gaorong Capital and Yunfeng Capital, with participation from a broad group of existing and new investors. Led by CEO Aaron Ren and founded in 2017, Sironax is positioning to progress its clinical programs targeting age-related degeneration.

Total raised

$200M

Funding rounds

1

Latest round

Series B

Latest activity

Aug 2022